Actively Recruiting
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Led by University of Miami · Updated on 2026-03-11
5478
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
CONDITIONS
Official Title
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Planning to undergo a primary total hip or knee arthroplasty
You will not qualify if you...
- History of venous thromboembolism
- Active malignancy
- Known prothrombotic condition
- Body mass index over 40
- Need for anticoagulation for other medical reasons
- Contraindication to aspirin or nonsteroidal anti-inflammatory drugs such as peptic ulcer disease or intolerance
- Not fluent in the language of the informed consent form
- Prisoners
- Pregnancy
- Mental illness or belonging to a vulnerable population
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Miami Hospital
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
R
Ramakanth Yakkanti, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here